Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas

Neoplasma

Volumn 59, Issue 5, 2012, Pages 508-515

  Smilek, P ^a   Neuwirthova, J ^a   Jarkovsky, J ^a   Dusek, L ^a   Rottenberg, J ^a   Kostrica, R ^a   Srovnal, J ^b   Hajduch, M ^b   Drabek, J ^b   Klozar, J ^c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

EGFR; EGFR gene expression; HNSCC; KRAS

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FEMALE; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSAL DISEASE; PROSPECTIVE STUDY; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN TOXICITY; TREATMENT RESPONSE; CANCER GRADING; CHEMORADIOTHERAPY; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; HEAD AND NECK TUMOR; MORTALITY; MUTATION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866770542     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_065     Document Type: Article

References (36)

1. BONNER JA, HARARI PM, GIRALT J, AZARNIA N, SHIN DM et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-678. http://dx.doi.org/10.1056/NEJMoa053422
2. TEMAM S, KAWAGUCHI H, EL-NAGGAR AK, JELINEK J, TANG H et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170. http://dx.doi.org/10.1200/JCO.2006.06.6605
3. EGLOFF AM, GRANDIS JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol 2008; 35: 286-297. http://dx.doi.org/10.1053/j.seminoncol.2008.03.008
4. BRAND TM, IIDA M, CHUNRONG L, WHEELER DL. The Nuclear Epidermal Growth Factor Receptor Signaling Network and Its Role in Cancer. Discov Med 2011; 12: 419-432.
5. SZABO B, NELHUBEL GA, KARPATI A, KENESSEY I, JORI B et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncology 2011; 47: 487-496. http://dx.doi.org/10.1016/j.oraloncology.2011.03.020
6. GAZDAR AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28(Suppl 1): 24-31. http://dx.doi.org/10.1038/onc.2009.198
7. WHEELER DL, DUNN EF HARARI PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature rewiewe Clin Oncol 2010; 7: 493-507.
8. VINCENZI B, SANTINI D, LOUPAKIS F, ADDEO R, LLIMPE FLR et al. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opin Biol Ther 2009; 9: 945-949. http://dx.doi.org/10.1517/14712590903081694
9. MUKOHARA T, ENGELMAN JA, HANNA NH, YEAP BY, KOBAYASHI S et al. Differential effects of gefitinib and cetuximab on non-small cell lung cancers bearing epidermal growth factor receptor mutations. J Nat Cancer Inst 2005; 97: 1185-1194. http://dx.doi.org/10.1093/jnci/dji238
10. LILENBAUM RC, JOHNSON B, LYNCH T, SANDLER A, BUNN P et al. The evolving role of cetuximab in non-small cell lung cancer. Clin Cancer Res 2006; 12: 4432-4435. http://dx.doi.org/10.1158/1078-0432.CCR-06-0097
11. ROSELL R, TARON M, REQUART N, ISLA D, MORAN T. Epidermal Growtht Factor Receptor Activ ation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway. Clin Cancer Res 2006; 12: 7222-7230. http://dx.doi.org/10.1158/1078-0432.CCR-06-0627
12. CHEN L F, COHEN E E, GRANDIS J R. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clinical Cancer Research 2010; 16: 2489-2495. http://dx.doi.org/10.1158/1078-0432.CCR-09-2318
13. NIU G, SUN X, CAO Q, COURTER D, KOONG A et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck quamous cell carcinoma. Clinical Cancer Research 2010; 16: 2095-2105. http://dx.doi.org/10.1158/1078-0432.CCR-09-2495
14. LIEVRE A, BACHET JB, LE CORRE D, BOIGE V, LANDI B et al. K-RAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006; 66: 3992-3995. http://dx.doi.org/10.1158/0008-5472.CAN-06-0191
15. DI FIORE F, BLANCHARD F, CHARBONNIER F, LE PESSOT F, LAMY A et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer 2007; 96: 1166-1169. http://dx.doi.org/10.1038/sj.bjc.6603685
16. RAE JM, SCHEYS JO, CLARK KM, CHADWICK RB, KIEFER MC et al. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 2004; 87: 87-95. http://dx.doi.org/10.1023/B:BREA.0000041585.26734.f9
17. TIDOW N, BOECKER A, SCHMIDT H, AGELOPOULOS K, BOECKER W et all. Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. Cancer Res 2003; 63: 1172-1178.
18. GURTNER K, DEUSE Y, BUTOF R, SCHAAL K, EICHELER W et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiotherapy and Oncology 2011; 99: 323-330. http://dx.doi.org/10.1016/j.radonc.2011.05.035
19. CHUNG CHH, ELY K, CARTER J, MCGAVRAN L, VARELLA-GARCIA M et al. High gene copy number of epidermal growth factor receptor by fluorescence in situ hybridization is frequent in head and neck squamous cell carcinomas and associates with worse recurrence-free survival. J Clin Oncol 2006; 24 (Suppl 18): 5502.
20. SOK JC, COPPELLI FM, THOMAS SM, LANGO MN, XI S et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical Cancer Research 2006; 12: 5064-5073. http://dx.doi.org/10.1158/1078-0432.CCR-06-0913
21. BARBER RD, HARMER DW, COLEMAN RA, CLARK BJL. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 2005; 21: 389-395. http://dx.doi.org/10.1152/physiolgenomics.00025.2005
22. SHINOJIMA N, TADA K, SHIRAISHI S, KAMIRYO T, KOCHI M et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63: 6962-6970.
23. LEEMANS CR, BRAAKHUIS BJM, BRAKENHOFF RH. The molecular biology of head and neck cancer. Nature Reviews Cancer 2011; 11: 9-22. http://dx.doi.org/10.1038/nrc2982
24. KERSTING C, PACKEISEN J, LEIDINGER B et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 2006; 59: 585-590. http://dx.doi.org/10.1136/jcp.2005.028373
25. MORONI M, VERONESE S, BENVENUTI S, MARRAPESE G, SARTORE-BIANCHI A et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancar: a cohort study. Lancet Oncol 2005; 6: 279-286. http://dx.doi.org/10.1016/S1470-2045(05)70102-9
26. VAN DAMME N, DERON P, VAN ROY N, DEMETTER P, BOLS A et al. Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010; 10: 189-198. http://dx.doi.org/10.1186/1471-2407-10-189
27. CHUNG CHH, ELY K, MCGAVRAN L, VARELLA-GARCIA M, PARKER J et al. Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas. Journal of Clinical Oncology 2006; 24: 4170-4176. http://dx.doi.org/10.1200/JCO.2006.07.2587
28. HIRSCH FR, VARELLA-GARCIA M, BUNN PA JR, DI MARIA MV, VEVE R et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807. http://dx.doi.org/10.1200/JCO.2003.11.069
29. PAEZ JG, JANNE PA, LEE JC, TRACY S, GREULICH H et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. http://dx.doi.org/10.1126/science.1099314
30. LYNCH TJ, BELL DW, SORDELLA R, GURUBHAGVATULA S, OKIMOTO RA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. http://dx.doi.org/10.1056/NEJMoa040938
31. BISSADA E, ABOU-CHACRA Z, WENG X, GUERTIN P, NGUYEN-TAN M et al. Prevalence of K-RAS codon 12 mutations in locally advanced head and neck squamous cell carcinoma and influence with regards to response to chemoradiation therapy. J Clin Oncol, Meeting Proceedings 2008; 26: Abstr 17008.
32. SHEIKH ALI MAL, GUNDUZ M, NAGATSUKA H, GUNDUZ E, CENGIZ B et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008; 99: 1589-1594. http://dx.doi.org/10.1111/j.1349-7006.2008.00861.x
33. HOA M, DAVIS SL, AMES SJ, SPANJAARD RA. Amplification of Wild-Type K-ras Promotes Growth of Head and Neck Squamous Cell Carcinoma. Cancer Res 2002; 62: 7154-7156.
34. JI H, ZHAO X, YUZA Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006;103: 7817-7822. http://dx.doi.org/10.1073/pnas.0510284103
35. CHAU NG, PEREZ-ORDONEZ B, ZHANG K, PHAM N, JAMES HO J et al. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck Oncology 2011; 3: 1-11.
36. BLAGOSKLONNY, M V. Gefitinib (lressa) in oncogen-adddictive cancers and therapy for common cancers. Cancer Biol Ther 2004; 3: 436-440. http://dx.doi.org/10.4161/cbt.3.5.984